Articles related to COMBINATION THERAPY

In patients with cisplatin-eligible muscle-invasive bladder cancer, perioperative enfortumab vedotin plus pembrolizumab improved event-free and overall survival compared with standard neoadjuvant gemcitabine-cisplatin chemotherapy in the phase 3 KEYNOTE-B15 trial.

Researchers identified a previously unrecognized B7-H3-driven pathway that promotes immune suppression in castration-resistant prostate cancer. Preclinical findings suggest dual targeting of B7-H3 and MEK signaling altered the tumor microenvironment and improved antitumor activity in experimental models.

A patient with PNH and persistent anemia during ravulizumab therapy experienced improved hemoglobin after danicopan was added, while an extended infusion delay highlighted treatment-continuity challenges without establishing protection from interrupted C5 inhibition.

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.